A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial. Standard therapy was associated with twice as many recurrences as compared with trabectedin, translating into a 40% reduction in the hazard for disease-free survival (DFS) in favor of trabectedin. […]